Surrozen, Inc (SRZN): Price and Financial Metrics

Surrozen, Inc (SRZN): $10.04

0.21 (-2.05%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add SRZN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#157 of 348

in industry

SRZN Price/Volume Stats

Current price $10.04 52-week high $16.19
Prev. close $10.25 52-week low $4.50
Day low $10.04 Volume 1,300
Day high $10.42 Avg. volume 14,601
50-day MA $10.27 Dividend yield N/A
200-day MA $9.25 Market Cap 32.12M

SRZN Stock Price Chart Interactive Chart >


Surrozen, Inc (SRZN) Company Bio


Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.


SRZN Latest News Stream


Event/Time News Detail
Loading, please wait...

SRZN Latest Social Stream


Loading social stream, please wait...

View Full SRZN Social Stream

Latest SRZN News From Around the Web

Below are the latest news stories about SURROZEN INC that investors may wish to consider to help them evaluate SRZN as an investment opportunity.

SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023

SRZN stock results show that Surrozen beat analyst estimates for earnings per share the second quarter of 2023.

InvestorPlace Earnings on InvestorPlace | December 14, 2023

SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023

SRZN stock results show that Surrozen missed analyst estimates for earnings per share the first quarter of 2023.

InvestorPlace Earnings on InvestorPlace | December 14, 2023

SRZN Stock Earnings: Surrozen Misses EPS for Q3 2023

SRZN stock results show that Surrozen missed analyst estimates for earnings per share the third quarter of 2023.

InvestorPlace Earnings on InvestorPlace | December 14, 2023

Surrozen Provides Third Quarter 2023 Financial Results

Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical trial in healthy volunteers in Q1 2024 Initiating Phase 1b studies in 2024 for SZN-043 in severe alcoholic hepatitis and SZN-1326 in moderate to severe ulcerative colitis Strengthened portfolio through two granted patents from the USPTO related to key discoveries involving the WNT pathway and its modulatio

Yahoo | November 8, 2023

Surrozen Provides Second Quarter 2023 Financial Results

SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023 Corporate prioritization efforts expected to provide cash runway extension into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company

Yahoo | August 9, 2023

Read More 'SRZN' Stories Here

SRZN Price Returns

1-mo 3.40%
3-mo -27.25%
6-mo 19.81%
1-year -2.94%
3-year -93.24%
5-year N/A
YTD 6.81%
2023 7.69%
2022 -90.96%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!